Category: MassDevice Q&A
Medtronic CFO Gary Ellis speaks to MassDevice about the company's just-released earnings, why the cardiac rhythm management market is depressed and whether there's been any fallout from canceling a GPO deal with Novation.
The waters around the good ship Medtronic Inc. (NYSE:MDT) have been a bit frothy these days.
Meg Spencer, CEO of laser manufacturer Hamilton Thorne Ltd., on how the company stays on the cutting edge of life science technology and its footprint in stem cells and regenerative medicine.
Laser-based lab equipment maker Hamilton Thorne Inc. (CVE:HTL) derives a major part of its revenues from the life sciences R&D market. CEO Meg Spencer says that requires the company to surf the leading edge of several life science research waves, including stem cells and regenerative medicine.
The Beverly, Mass.-based company looks to help solve some of the problems scientists encounter as they develop their research on stem cells into regenerative medicine techniques. Those often involve the growth of millions — or even billions — of cells, so anything that can accelerate or automate that process is vital to innovation in the space.
BG Medicine's biggest innovation isn't its test to predict heart failure, according to CEO Dr. Pieter Muntendam — it's the first-of-its-kind business model for diagnostics development the company is pioneering.
When BG Medicine (NSDQ:BGMD) took itself public last month, three years after first announcing (then scuttling) its first initial public offering, investors seemed to like what they saw. Sure, the company cut its share price in half just ahead of the $7-per-share offering Feb. 11, but shares have averaged nearly $8.41 since then — a 20.1 percent increase.*
Rahul Aras, the CEO of SironRX Therapeutics and Juventas Therapeutics, on the challenges of his dual role and his companies' stem-cell-based technology.
Many business professionals likely dream of the day when they’ll run a company as chief executive, but how many hope to lead two start-ups simultaneously?
We're on the cusp of a significant new era in medical device design, Nano Surfaces CEO Joe Gatto tells MassDevice, in which their very surfaces will build themselves and be able to operate at the molecular level.
Coming generations of implanted medical devices will interact with the human body at the molecular level, using sophisticated nano-coatings to not only thwart microbial growth but to perform biological operations.
That's the prediction of Nano Surfaces founder, president and CEO Joe Gatto. The Boston-based firm is developing technology it's licensed from Cornell University to create self-assembling, anti-microbial coatings on a nanotech scale — and Gatto says that's just the beginning. To prove it, he's hitting to road to raise a Series A round from institutional investors.
Nfocus CEO Eric Milledge tells MassDevice that the Palo Alto company is focused on the long term, intent on changing the way brain aneurysms are treated.
NFocus Neuromedical Inc. is developing a new treatment for brain aneurysms that could end up giving companies like Johnson & Johnson (NYSE:JNJ), Stryker (NYSE:SYK) and Covidien (NYSE:COV) a real headache.
Semprus BioSciences Corp. hopes to reduce the 60,000 deaths and $11 billion in costs related to "surface failures" of vascular catheters with its Sustain technology for coating medical devices.
Medical device developers have long sought to reduce the risks involved with implants by applying coatings to prevent both bacteria and blood from sticking to the objects once they're inside the body.
But coatings can wear off or otherwise lose their effectiveness. Semprus BioSciences Inc. is developing a solution to this fundamental limitation of implanted medical devices with its Sustain technology, which CEO David Lucchino describes as a "physical extension" of the device's material.